Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Jenna Rossoff; Christina Baggott; Snehit Prabhu; Holly Pacenta; Christine L. Phillips; Heather Stefanski; Julie An Talano; Amy Moskop; Steven P. Margossian; Michael R. Verneris; Gary Douglas Myers; Nicole Karras; Patrick A. Brown; Muna Qayed; Michelle Hermiston; Prakash Satwani; Christa Krupski; Amy K. Keating; Rachel Wilcox; Cara A. Rabik; Vanessa A. Fabrizio; Michael Kunicki; Vasant Chinnabhandar; A. Yasemin Goksenin; Kevin J. Curran; Crystal L. Mackall; Theodore W. Laetsch; Liora M. Schultz

doi:10.1182/blood.2021012392

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Jenna Rossoff^*, Christina Baggott, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Heather Stefanski, Julie An Talano, Amy Moskop, Steven P. Margossian, Michael R. Verneris, Gary Douglas Myers, Nicole Karras, Patrick A. Brown, Muna Qayed, Michelle Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel Wilcox, Cara A. RabikVanessa A. Fabrizio, Michael Kunicki, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Liora M. Schultz

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	2138-2142
Number of pages	5
Journal	Blood
Volume	138
Issue number	21
DOIs	https://doi.org/10.1182/blood.2021012392
State	Published - Nov 25 2021

Funding

Conflict-of-interest disclosure: C.L.P. has served on an advisory committee for Novartis. H.S. has served on an advisory committee and as a member of the Speakers Bureau for Novartis. S.P.M. has served on an advisory committee for Novartis and Jazz Pharmaceuticals. M.R.V. has served on an advisory committee for Novartis, has been a consultant for and is a current equity holder in Fate Therapeutics and B-MoGen Biotechnologies, and has been a consultant for UpToDate. G.D.M. has served on the ELIANA trial Steering Committee and Speakers Bureau and has served as a consultant and received honoraria from Novartis. P.A.B. has served on an advisory committee for Novartis, Kite, Takeda, Janssen, Kura, Servier, and Jazz Pharmaceuticals. M.Q. has served as a consultant for Novartis and Mesoblast. M.H. has served on an advisory board for Sobi and Novartis. P.S. has served as a consultant for Takeda and Mesoblast. K.J.C. has served as a consultant for and received research funding from Novartis, has served as a consultant for Mesoblast, and received research funding from Celgene. C.L.M. has served as a consultant for and is a current equity holder in Lyell Immunopharma and Apricity Health, has served as a consultant for NeoImmune Tech, Nektar Therapeutics, and Bristol Myers Squibb, and is a current equity holder in Allogene. T.W.L. reports consultancy relationships with Novartis, Cellectis, Bayer, Deciphera, Jumo Health, and Y-mAbs Therapeutics and has received research funding from Pfizer, Novartis, and Bayer. The remaining authors declare no competing financial interests.

ASJC Scopus subject areas

Hematology
Biochemistry
Cell Biology
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood.2021012392

Cite this

Rossoff, J., Baggott, C., Prabhu, S., Pacenta, H., Phillips, C. L., Stefanski, H., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., Wilcox, R., ... Schultz, L. M. (2021). Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood, 138(21), 2138-2142. https://doi.org/10.1182/blood.2021012392

@article{b7e50bddcf5a4fa49674f44472f0e729,

title = "Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia",

author = "Jenna Rossoff and Christina Baggott and Snehit Prabhu and Holly Pacenta and Phillips, {Christine L.} and Heather Stefanski and Talano, {Julie An} and Amy Moskop and Margossian, {Steven P.} and Verneris, {Michael R.} and Myers, {Gary Douglas} and Nicole Karras and Brown, {Patrick A.} and Muna Qayed and Michelle Hermiston and Prakash Satwani and Christa Krupski and Keating, {Amy K.} and Rachel Wilcox and Rabik, {Cara A.} and Fabrizio, {Vanessa A.} and Michael Kunicki and Vasant Chinnabhandar and Goksenin, {A. Yasemin} and Curran, {Kevin J.} and Mackall, {Crystal L.} and Laetsch, {Theodore W.} and Schultz, {Liora M.}",

note = "Funding Information: Conflict-of-interest disclosure: C.L.P. has served on an advisory committee for Novartis. H.S. has served on an advisory committee and as a member of the Speakers Bureau for Novartis. S.P.M. has served on an advisory committee for Novartis and Jazz Pharmaceuticals. M.R.V. has served on an advisory committee for Novartis, has been a consultant for and is a current equity holder in Fate Therapeutics and B-MoGen Biotechnologies, and has been a consultant for UpToDate. G.D.M. has served on the ELIANA trial Steering Committee and Speakers Bureau and has served as a consultant and received honoraria from Novartis. P.A.B. has served on an advisory committee for Novartis, Kite, Takeda, Janssen, Kura, Servier, and Jazz Pharmaceuticals. M.Q. has served as a consultant for Novartis and Mesoblast. M.H. has served on an advisory board for Sobi and Novartis. P.S. has served as a consultant for Takeda and Mesoblast. K.J.C. has served as a consultant for and received research funding from Novartis, has served as a consultant for Mesoblast, and received research funding from Celgene. C.L.M. has served as a consultant for and is a current equity holder in Lyell Immunopharma and Apricity Health, has served as a consultant for NeoImmune Tech, Nektar Therapeutics, and Bristol Myers Squibb, and is a current equity holder in Allogene. T.W.L. reports consultancy relationships with Novartis, Cellectis, Bayer, Deciphera, Jumo Health, and Y-mAbs Therapeutics and has received research funding from Pfizer, Novartis, and Bayer. The remaining authors declare no competing financial interests.",

year = "2021",

month = nov,

day = "25",

doi = "10.1182/blood.2021012392",

language = "English (US)",

volume = "138",

pages = "2138--2142",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "21",

}

Rossoff, J, Baggott, C, Prabhu, S, Pacenta, H, Phillips, CL, Stefanski, H, Talano, JA, Moskop, A, Margossian, SP, Verneris, MR, Myers, GD, Karras, N, Brown, PA, Qayed, M, Hermiston, M, Satwani, P, Krupski, C, Keating, AK, Wilcox, R, Rabik, CA, Fabrizio, VA, Kunicki, M, Chinnabhandar, V, Goksenin, AY, Curran, KJ, Mackall, CL, Laetsch, TW & Schultz, LM 2021, 'Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia', Blood, vol. 138, no. 21, pp. 2138-2142. https://doi.org/10.1182/blood.2021012392

TY - JOUR

T1 - Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

AU - Rossoff, Jenna

AU - Baggott, Christina

AU - Prabhu, Snehit

AU - Pacenta, Holly

AU - Phillips, Christine L.

AU - Stefanski, Heather

AU - Talano, Julie An

AU - Moskop, Amy

AU - Margossian, Steven P.

AU - Verneris, Michael R.

AU - Myers, Gary Douglas

AU - Karras, Nicole

AU - Brown, Patrick A.

AU - Qayed, Muna

AU - Hermiston, Michelle

AU - Satwani, Prakash

AU - Krupski, Christa

AU - Keating, Amy K.

AU - Wilcox, Rachel

AU - Rabik, Cara A.

AU - Fabrizio, Vanessa A.

AU - Kunicki, Michael

AU - Chinnabhandar, Vasant

AU - Goksenin, A. Yasemin

AU - Curran, Kevin J.

AU - Mackall, Crystal L.

AU - Laetsch, Theodore W.

AU - Schultz, Liora M.

N1 - Funding Information: Conflict-of-interest disclosure: C.L.P. has served on an advisory committee for Novartis. H.S. has served on an advisory committee and as a member of the Speakers Bureau for Novartis. S.P.M. has served on an advisory committee for Novartis and Jazz Pharmaceuticals. M.R.V. has served on an advisory committee for Novartis, has been a consultant for and is a current equity holder in Fate Therapeutics and B-MoGen Biotechnologies, and has been a consultant for UpToDate. G.D.M. has served on the ELIANA trial Steering Committee and Speakers Bureau and has served as a consultant and received honoraria from Novartis. P.A.B. has served on an advisory committee for Novartis, Kite, Takeda, Janssen, Kura, Servier, and Jazz Pharmaceuticals. M.Q. has served as a consultant for Novartis and Mesoblast. M.H. has served on an advisory board for Sobi and Novartis. P.S. has served as a consultant for Takeda and Mesoblast. K.J.C. has served as a consultant for and received research funding from Novartis, has served as a consultant for Mesoblast, and received research funding from Celgene. C.L.M. has served as a consultant for and is a current equity holder in Lyell Immunopharma and Apricity Health, has served as a consultant for NeoImmune Tech, Nektar Therapeutics, and Bristol Myers Squibb, and is a current equity holder in Allogene. T.W.L. reports consultancy relationships with Novartis, Cellectis, Bayer, Deciphera, Jumo Health, and Y-mAbs Therapeutics and has received research funding from Pfizer, Novartis, and Bayer. The remaining authors declare no competing financial interests.

PY - 2021/11/25

Y1 - 2021/11/25

UR - http://www.scopus.com/inward/record.url?scp=85119700502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119700502&partnerID=8YFLogxK

U2 - 10.1182/blood.2021012392

DO - 10.1182/blood.2021012392

M3 - Letter

C2 - 34499715

AN - SCOPUS:85119700502

SN - 0006-4971

VL - 138

SP - 2138

EP - 2142

JO - Blood

JF - Blood

IS - 21

ER -

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this